Reading view
Development of a Data-Based Method for Predicting Nursing Workload in an Acute Care Hospital: Methodological Study
Behavior Change Strategies in Digital Exercise Interventions for Adolescent Idiopathic Scoliosis: Scoping Review
AI designs de novo antibiotics
Nature Biotechnology, Published online: 15 September 2025; doi:10.1038/s41587-025-02822-6
AI designs de novo antibioticsGoogle launches new protocol for agent-driven purchases
A Practical Guide to Using Futures Methods in Health Care: Approaches, Applications, and Case Studies
Ready or not, the digital afterlife is here
Nature, Published online: 15 September 2025; doi:10.1038/d41586-025-02940-w
Developers of griefbots say that they help people by allowing them to commune with recreations of the dead, but others say that the technology is fraught with danger.Digital Health Technology Infrastructure Challenges to Support Health Equity in the United States: Scoping Review
Prompt Engineering in Clinical Practice: Tutorial for Clinicians
Hugging Face Releases FinePDFs: a 3-Trillion-Token Dataset Built from PDFs

Hugging Face has unveiled FinePDFs, the largest publicly available corpus built entirely from PDFs. The dataset spans 475 million documents in 1,733 languages, totaling roughly 3 trillion tokens. At 3.65 terabytes in size, FinePDFs introduces a new dimension to open training datasets by tapping into a resource long considered too complex and expensive to process.
By Robert KrzaczyńskiDo startups still need Silicon Valley? Leaders at SignalFire, Lago, and Revolution debate at TechCrunch Disrupt 2025
Multicancer Detection Tests Not Ready for Prime Time, Review Suggests
(MedPage Today) -- The jury is still out on the merits of multicancer detection (MCD) tests in asymptomatic adults, according to results from a systematic review.
Across 20 studies reporting on the accuracy of 19 tests, test sensitivity ranged... Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
Nature Medicine, Published online: 15 September 2025; doi:10.1038/s41591-025-03965-4
A brief, self-administered digital cognitive test, in combination with a blood test, accurately detects clinical Alzheimer’s disease in primary care.We Need to Change Our Healthcare System. Can We Find the Will to Do It?
(MedPage Today) -- I took our new puppy Archie out for a walk to get him used to the New York City streets -- the sights, the sounds, the smells -- and it seemed like everyone wanted to stop and say hello to him.
Everyone loves a puppy.
We... US government slams mRNA vaccine research
Nature Biotechnology, Published online: 15 September 2025; doi:10.1038/s41587-025-02826-2
US government slams mRNA vaccine researchPrognostic Value of Circulating Tumor DNA in HR+/HER2- Stage I-III Breast Cancer: A Systematic Review
Cancers (Basel). 2025 Aug 29;17(17):2831. doi: 10.3390/cancers17172831.
ABSTRACT
Background: Hormone receptor-positive (HR+), HER2-negative breast cancer accounts for the majority of breast cancer diagnoses. While outcomes have improved with neoadjuvant and adjuvant therapies, the risk of late recurrence persists, and there remains a critical need for reliable biomarkers to guide prognosis and post-treatment surveillance. Circulating tumor DNA (ctDNA), detectable via liquid biopsy, has emerged as a promising tool for monitoring minimal residual disease and predicting survival outcomes. This systematic review evaluates the association between ctDNA detection during neoadjuvant or adjuvant treatment and survival outcomes in early-stage HR+/HER2- breast cancer. Methods: This systematic review was conducted in accordance with PRISMA guidelines. A comprehensive literature search of Ovid MEDLINE and Embase was conducted to identify studies published through 3 May 2024 that evaluated ctDNA as a prognostic biomarker in stage I-III HR+/HER2- breast cancer. We included studies reporting recurrence-free survival, invasive disease-free survival, or overall survival and excluded non-original studies, conference abstracts, and non-English articles. Data extraction and qualitative synthesis were performed, and the risk of bias was qualitatively assessed across studies. No review protocol was registered. Results: Eleven studies comprising 1644 patients met the inclusion criteria. In the neoadjuvant setting, ctDNA positivity prior to treatment initiation was associated with inferior survival outcomes. In the adjuvant setting, detection of ctDNA during or after treatment was consistently linked to poorer recurrence-free and invasive disease-free survival. Across studies, ctDNA detection was a significant negative prognostic marker. Conclusions: This systematic review supports the prognostic value of ctDNA in HR+/HER2- early-stage breast cancer. Limitations include small sample sizes, observational study designs, and heterogeneity in ctDNA assays. Standardization of ctDNA testing methods and further prospective trials are needed to validate its clinical utility and explore its potential role in guiding therapeutic interventions.
PMID:40940926 | PMC:PMC12427406 | DOI:10.3390/cancers17172831
Functions of the global health system in a new era
Nature Medicine, Published online: 11 September 2025; doi:10.1038/s41591-025-03936-9
In an irrevocably changed landscape, reform of the global health system needs to answer key questions on functions, what should be delivered in different contexts and at different levels, and how the system should operate.Interventions Based on Biofeedback Systems to Improve Workers’ Psychological Well-Being, Mental Health, and Safety: Systematic Literature Review
An end-to-end solution for out-of-hospital emergency medical dispatch triage based on multimodal and continual deep learning
Publication date: December 2025
Source: Artificial Intelligence in Medicine, Volume 170
Author(s): Pablo Ferri, Carlos Sáez, Antonio Félix-De Castro, Purificación Sánchez-Cuesta, Juan M. García-Gómez